Graft Polymer (UK) PLC ( ) just unveiled an update. Graft Polymer (UK) Plc announced the successful approval of a name change to Solvonis Therapeutics plc following a general meeting.

Graft Polymer (UK) PLC (GB:GPL) has released an update.Don't Miss our Black Friday Offers:Unlock your investing potential with TipRanks Premium - Now At 40% OFF!Make smarter investments with ...

Dec 05, 2023: Polymer-grafting approach facilitates fabrication of surface-functionalized MOF nanosheets (Nanowerk Spotlight) Researchers are exploring two-dimensional (2D) metal-organic frameworks ...

Graft Polymer (UK) plc has announced a research agreement between its partner, Awakn Life Sciences Corp., and the University of Nottingham. The agreement covers in vivo research to evaluate the ...

Revenue: UK£587.0k (up 8.3% from FY 2022). Net loss: UK£3.12m (loss widened by 15% from FY 2022). UK£0.03 loss per share (further deteriorated from UK£0.026 loss in FY 2022). What about risks? Every ...

Graft Polymer said it is focused on "expanding its product ranges and global footprint, establishing partnerships to help it compete effectively through cutting edge R&D and production methods".

(Alliance News) - Graft Polymer (UK) PLC on Monday said it will collaborate with the Slovenian Faculty of Polymer Technology to research and produce vitrimer polymer products. The London-based ...

(Graft Polymer (UK) PLC (LSE:GPL) CEO Anthony Tennyson talked with Proactive's Stephen Gunnion about the company’s plans to acquire Canadian biotech Awakn Life Sciences. Tennyson explained the ...

Graft Polymer’s core business comprises polymer modification and the development of drug delivery systems Graft Polymer (UK) PLC’s first half-year earnings call following admission to the ...